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Abstract
The mass spectrometry-based peptidomics approaches have proven its usefulness in several areas such as the discovery of
physiologically active peptides or biomarker candidates derived from various biological fluids including blood and
cerebrospinal fluid. However, to identify biomarkers that are reproducible and clinically applicable, development of a novel
technology, which enables rapid, sensitive, and quantitative analysis using hundreds of clinical specimens, has been eagerly
awaited. Here we report an integrative peptidomic approach for identification of lung cancer-specific serum peptide
biomarkers. It is based on the one-step effective enrichment of peptidome fractions (molecular weight of 1,000–5,000) with
size exclusion chromatography in combination with the precise label-free quantification analysis of nano-LC/MS/MS data set
using Expressionist proteome server platform. We applied this method to 92 serum samples well-managed with our SOP
(standard operating procedure) (30 healthy controls and 62 lung adenocarcinoma patients), and quantitatively assessed the
detected 3,537 peptide signals. Among them, 118 peptides showed significantly altered serum levels between the control
and lung cancer groups (p,0.01 and fold change .5.0). Subsequently we identified peptide sequences by MS/MS analysis
and further assessed the reproducibility of Expressionist-based quantification results and their diagnostic powers by MRM-
based relative-quantification analysis for 96 independently prepared serum samples and found that APOA4 273–283, FIBA
5–16, and LBN 306–313 should be clinically useful biomarkers for both early detection and tumor staging of lung cancer.
Our peptidome profiling technology can provide simple, high-throughput, and reliable quantification of a large number of
clinical samples, which is applicable for diverse peptidome-targeting biomarker discoveries using any types of biological
specimens.
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Introduction
Lung cancer is the leading cause of cancer death worldwide [1].
Smoking is still the leading risk factor for lung cancer, but recently
the proportion of never smoker-related lung cancer is significantly
increasing, although its cause or other risk factor(s) is unknown [2].
Lung cancer patients show the poor prognosis with an overall 5-
year survival rate of only 15% [3]. One of the reasons for this
dismal prognosis is no effective tools to detect it at an early stage
and in fact only 16% of patients are diagnosed at their early stage
of the disease [3]. Current screening methods such as chest X-ray
or cytological examination of sputum have not yet shown their
effectiveness in the improvement of mortality of lung cancer,
whereas low dose helical CT have been proved to possess a
potential to detect early-stage lung cancer and demonstrate 20%
lower lung cancer mortality rate compared to chest X-ray
screening [4]. On the other hand, serum biomarkers for lung
cancer have been investigated to achieve early detection of the
disease and improve clinical management of patients [5].
Nonetheless, their present clinical usefulness remains limited
[6,7]. CEA (carcinoembryonic antigen) and CYFRA (cytokeratin
19 fragment) are elevated in sera in a subset of lung cancer
patients, and are clinically applied to monitor the disease status
and evaluate the response to treatments. However, they are not
recommended to use in clinical diagnosis and screening [8]
because they are also elevated in certain non-cancerous conditions
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other types of cancers. It is obvious that CEA and CYFRA do not
have the sufficient power to apply for the screening of early-stage
lung cancer. Hence, development of novel serum/plasma
biomarkers applicable for lung cancer diagnosis is urgently
required.
Recently monitoring the protein expression pattern in clinical
specimens by proteomics technologies has offered great opportu-
nities to discover potentially new biomarkers for cancer diagnosis.
Various proteomic tools such as 2D-DIGE, SELDI-TOF-MS,
protein arrays, ICAT, iTRAQ and MudPIT have been used for
differential analysis of biological samples including cell lysates and
blood to better understand the molecular basis of cancer
pathogenesis and the characterization of disease-associated
proteins [9]. In order to explore putative biomarkers in
complicated biological samples, focused proteomics or targeted
proteomics technologies have been utilized such as; phosphopro-
tein enrichment technologies IMAC [10], the cell-surface-
capturing (CSC) technology [11,12], glycan structure-specific
quantification technology IGEL [13]. Most recently, to identify
novel lung cancer biomarkers, Ostroff et al. reported the aptamer-
based proteomic technology targeting 813 known proteins. Finally
they selected 12 proteins which discriminated NSCLC from
controls with 89% sensitivity and 83% specificity [14]. Thus
targeted proteomics technologies such as the aptamer method
would be applicable for the measurement of already known
proteins, however could not be applied for the discovery of
biomarkers targeting unknown proteins, post translational modi-
fications, or biologically-processed polypeptides.
These methods can circumvent the technological limitations
that currently prohibit the sensitive and high-throughput profiling
of, in particular, blood proteome samples because of its high
complexity and large dynamic range of proteins. The peptidome
profiling technology addressed in the present study is one of the
focused proteomics approaches targeting on biosynthetic frag-
ments of proteins/peptides in blood, involving bioactive peptides
and those non-specifically degraded by proteases or peptidases
[15,16].
So far more than 500 proteases/peptidases are known to be
expressed in human cells [17,18]. They function at almost all
locations in the body including intracellular region, extracellular
matrices, and in blood, involved in activation of other protein
functions, degradation of cellular proteins, and notably tumor
progression or suppression [19,20,21]. Indeed many matrix
metalloproteases are overexpressed in various types of tumor cells,
that facilitate construction of favorable micro-environment for
tumor cells or promotion of metastasis[21]. Definitely these
protease/peptidase activities should result in the production of
digested peptide fragments well reflecting the tumor progression or
tumor-associated responses. Thus peptidomic profiling of human
serum or plasma is a promising tool for the discovery of novel
tumor markers.
In this article, we extracted peptidome fractions (molecular
weight ,5,000 Da) from 92 individuals using the well-established
and reproducible one-step peptidome enrichment method based
on size exclusion chromatography (SEC) [22,23] and provided
them to the label-free mass spectrometric quantification analysis
combined with the statistical analyses on Expressionist proteome
server platform. Our rapid and simple peptidome enrichment
procedure can circumvent both less reproducible peptidome
extraction by such as ultrafiltration spin filters and prolonged
sample preparation including immuno-depletion column chroma-
tography, denaturing proteins, buffer exchange, ultrafiltration, and
so on [16]. After quantitative comparison of 3,537 serum peptides
among 92 cases in the lung cancer biomarker discovery, we further
evaluated the accuracy of quantification results by another more
reliable quantification method MRM (multiple reaction monitor-
ing) technology using independently prepared 96 serum samples.
Materials and Methods
Serum samples
All human serum samples were obtained with informed consent
from 122 patients with lung adenocarcinoma (stage I to IV) at
Hiroshima University Hospital at the examination on admission.
Serum samples as normal controls were also obtained with
informed consent from 30 healthy volunteers who received
medical checkup at Hiroshima NTT Hospital and 36 from Kochi
University Hospital. Each consent above was given in writing. To
circumvent undesirable degradation of proteins and peptides, all
serum samples were collected and stored under unified SOP.
Briefly, all venous blood specimens were collected with vacuum
blood collection tubes TERUMO VP-P070K (TERUMO, Tokyo,
Japan). After staying upright at ambient temperature for 60
minutes, serum fractions were separated with centrifugation at
1500 x g for 15 min (4uC) and immediately stored at 280 uC. One
freeze-and-thaw procedure was permitted for any serum samples
used in the present study. This study was approved by individual
institutional ethical committees; The Ethical Committee of
Yokohama Institute, RIKEN (Approval code: Yokohama H20-
12), The Ethical Committee of Hiroshima University Hospital,
and The Ethical Committee of Kochi University Hospital.
Heat inactivation of sera and subsequent peptidome
enrichment
All serum samples were freezed and thawed once and
immediately incubated at 100 uC for 10 minutes after 4 times
dilution with proteomics grade water. Following filtration with
Spin-X 0.45 mm spin filters (Corning Incorporated, Corning, NY,
USA), samples were loaded into 10/300 Superdex peptide column
(GE Healthcare UK Ltd., Buckinghamshire, England) coupled
with Prominence HPLC system (Shimadzu Corporation, Kyoto,
Japan). The peptidome fraction was collected from 22 to 34
minutes in the constant flow of 100 mM ammonium acetate at
0.5 ml/min flow rate. The collected fractions were dried-up with
Vacuum Spin Drier (TAITEC Co., Ltd., Saitama, Japan).
LC/MS/MS analysis for the screening study
The dried peptide samples were resuspended in 2% acetonitrile
with 0.1% trifluoroacetic acid and analyzed by QSTAR-Elite mass
spectrometer (AB Sciex, Foster City, CA, USA) combined with
UltiMate 3000 nano-flow HPLC system (DIONEX Corporation,
Sunnyvale, CA, USA). Samples were separated on the
100 mm6200 mm tip-column (GL Sciences Inc., Tokyo, Japan),
in which L-Column beads (Chemicals Evaluation and Research
Institute, Tokyo, Japan) were manually loaded, using solvent A
[0.1% formic acid, 2% acetonitrile] and solvent B [0.1% formic
acid, 70% acetonitrile] with the multistep linear gradient of solvent
B 5 to 55% for 95 minutes and 55 to 95% for 10 minutes at a flow
rate 200 nl/min. The elute was directly analyzed with the 1
second MS survey (m/z 400–1800) followed by three MS/MS
measurements on the most intense parent ions (30 counts
threshold, +2-+4 charge state, and m/z range 50–2000), using
the ‘‘smart exit’’ setting (SIDA=3.0, max accumulation time
=2.0 sec.). Previously targeted parent ions were excluded from
repetitive MS/MS acquisition for 40 seconds (100 mDa mass
tolerance). The other parameters on QSTAR-Elite were shown as
follows: DP =60, FP =265, DP2 =15, CAD =5, IRD =6,
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mass of each run was calibrated using three typical polysiloxane-
derived background peaks: m/z =445.12003, 519.13882, and
667.17640. The resolution of mass spectra was around 20,000 at
m/z =400. The primary data files (formatted as wiff and
wiff.scan) from 92 clinical samples are available in a public
repository site Proteome Commons (https://proteomecommons.
org/). The MASCOT database search was performed on the
Analyst QS 2.0 software (AB Sciex, Foster City, CA, USA). The
MS/MS data was searched against the human protein database
from SwissProt 57.4 (20,400 sequences) using the search
parameters: Taxonomy = Homo sapiense, Enzyme = None,
Fixed modifications = None, Variable modifications = Oxida-
tion (Met), MS tolerance =50 ppm, and MS/MS tolerance =
0.1 Da, with Mascot Automatic Decoy Search. Although Matrix
Science recommends to use the Homology threshold for less-
stringent criteria or Identity threshold providing almost same
protein identification numbers with the criteria Expectation value
,0.05 (http://www.matrixscience.com/help/interpretation_-
help.html), we accepted peptide identifications that satisfied both
the false discovery rate (FDR) of peptide matches above identity
threshold less than 5% and the Expectation value ,0.05 in order
to obtain more reliable identification of individual peptides than
that from Mascot default criteria.
Alignment of MS chromatogram planes and peak
detection on Expressionist RefinerMS
The raw data files from QSTAR-Elite (.wiff and wiff.scan
formatted) were directly loaded onto the Genedata Expressionist
modules (Genedata AG, Basel, Switzerland). Genedata Expression-
ist worked on the in-house server system HP-DL380-G5 (Hewlett-
Packard Development Company, Palo Alto, CA, USA) equipped
with 16 GB memory, (72 GB62) + (146 GB625) RAID 0+1 hard
disks, and SUSE Linux Enterprise Server 10 SP2 operating system,
installed with Oracle 10 g ver. 10.2.0.4. software (Oracle Corpo-
ration, Redwood Shores, CA, USA). All MS chromatograms were
smoothed with RT Window =3 scans in the Chromatogram
Chemical Noise Subtraction Activity. To remove the background
noise, a peak intensity is defined as follows.
Intensitysubtracted~
max(Intensityoriginal {Quantile{Threshold,0)
Here, values Quantile =50%, Intensity Threshold =15 cps
were used. Furthermore signals satisfying at least one of the
following criteria were considered as noise peaks and subtracted:
RT Window .50 scans, Minimum RT Length =4 scans, or
Minimum m/z Length =8 data points. Then MS chromatogram
planesderived from 92serum samples wereaccuratelyaligned using
parameters: m/z Window =0.1 Da, RT Window =0.2 min, Gap
Penalty =1, and RT Search Interval =5 min in the Chromato-
gram RT Alignment Activity. Next, the Summed Peak Detection
Activity detected the peaks on a temporaryaveraged chromatogram
with parameters as follows: Summation Window =5 scans,
Overlap =50, Minimum Peak Size =4 scans, Maximum Merge
Distance =10 data points, Gap/Peak Ratio =1, Method =
curvature-based peak detection, Peak Refinement Threshold =5,
Consistency Filter Threshold =0.8, Signal/Noise Threshold =1.
Finally the two steps Summed Isotope Clustering Activity identified
isotope patterns among 2D peaks, in which peaks identified as
belonging to the same isotope pattern of a molecule were grouped
into peak clusters. The first clustering was performed with the
following criteria: Minimum Charge =1, Maximum Charge =10,
Maximum Missing Peaks =0, First Allowed Gap Position =3,
Ionization =protonation, RT Tolerance =0.1 min, m/z Toler-
ance =0.05 Da, Isotope Shape Tolerance =10.0, and Minimum
Cluster Size Ratio =1.2.The second clustering was performed with
the same setting above, except for Minimum Cluster Size Ratio
=0.6 and Reuse Existing Clusters = true. The information of all
detected cluster peaks, including m/z, retention time, and intensity,
was exported as ABS files.
Label-free quantification and statistical analysis on
Expressionist Analyst
The ABS files were loaded on the Expressionist Analyst module
(Genedata AG, Basel, Switzerland). The peak intensity variation
among 32 samples was normalized by fixing the median intensity
of each sample at 10,000. Using the normalized intensity data,
Student’s t-test was performed between the normal group (n=30)
and lung cancer patients group (n=62). The candidate biomarker
peaks were extracted which showed p,0.01 and fold-change .5.0
between two groups. The candidates were further selected by
Absent/Present Search to identify peaks with all-or-nothing
detection pattern, which were detectable in 15 or all of 16 samples
in one group and 1 or none of 16 samples in another group.
Multiple Reaction Monitoring
Serum samples were processed with Superdex peptide column
chromatography as described above before mass spectrometric
analyses. The dried peptide samples were resuspended with 1
fmol/ml BSA tryptic digest solution in 2% acetonitrile, 0.1%
trifluoroacetic acid and analyzed by 4000 QTRAP mass
spectrometer (AB Sciex, Foster City, CA, USA) combined with
Paradigm MS4 PAL nano-flow HPLC system (AMR Inc., Tokyo,
Japan). Peptides were separated on the 100 mm6100 mm tip-
column (GL Sciences Inc., Tokyo, Japan), in which L-Column
ODS beads (Chemicals Evaluation and Research Institute,
Saitama, Japan) were manually loaded. Using solvent A [0.1%
formic acid, 2% acetonitrile] and solvent B [0.1% formic acid,
90% acetonitrile], the linear gradient of solvent B 2 to 100% for 10
minutes was configured at a flow rate 200 nl/min. 19 targeted
peptide ions and 5 BSA-derived peptide ions were simultaneously
monitored by the MRM mode in Analyst 1.5 software (AB Sciex,
Foster City, CA, USA) in duplicate. The MRM transitions are
shown in Table S4. The acquired MRM chromatograms were
then smoothened and quantified with MultiQuant software (AB
Sciex, Foster City, CA, USA). MRM peak areas in each sample
were normalized as follows:
AreaNormalized~
AreaRaw data=(summed area of 5 BSA standards)|1000
Box plot analysis and ROC curve analysis
The averaged area of the duplicated MRM chromatogram peak
corresponding to 19 candidate biomarker peptides was used to
create box plot with R algorithm. For each study the box represents
the middle half of the distribution of the data points stretching from
the 25
th percentile to the 75
th percentile. The line across the box
represents the median. The lengths of the lines above and below the
box are defined by the maximum and minimum datapoint values,
respectively, that lie within 1.5 times the spread of the box. Results
of Student’s t-test were included on the box plot. ROC curves were
also depicted by R. The cut-off value was set at the point whose
Peptidome Profiling for Lung Tumormarker Discovery
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minimum. The sensitivity (Sens), specificity (Spec), positive
predictive value (PV+), negative predictive value (PV-), and are
under the curve (AUC) were shown on each graph.
Results
The efficient enrichment of peptidome fractions from
sera
Since reproducible and accurate separation of the peptidome
fraction from serum was essential for the effective screening of
biomarkers, we optimized a simple gel filtration chromatography
method (Fig. 1) and evaluated the peptide recovery. To avoid
uncontrolled degradation of serum components arising from intact
proteases and peptidases, all serum samples were immediately heated
at 100 uC for 10 min after only one freeze-thaw procedure. Four-fold
dilution of serum with water could eliminate the protein aggregation
during heat inactivation even though the samples appeared slightly
cloudy. Figure 2A shows the merged gel filtration HPLC chromato-
grams from 16 individual serum samples using the Superdex Peptide
10/300 column. The spectra illustrated highly reproducible separa-
tion of serum proteins and peptides. Then, the accuracy of size
exclusion chromatography was assessed by analyzing 10 fractions
(2 min each from retention time for the period of 14–34 min, Fig. 2B)
with the MALDI-TOF-TOF mass spectrometer (Fig. 2C). As shown
by the continuous MS spectra in Figure 2C, our gel filtration
chromatography procedure allowed precise separation of serum
proteins and peptides based on their molecular weights. Consequent-
ly we defined the fraction numbers 5 to 10 (corresponding to
molecularweight1,000 to 5,000)thatshould befocusedinthefurther
biomarker screening and validation studies.
Label-free quantification-based peptide biomarker
screening for lung cancer
To explore serum peptides which could be applied for early
detection of lung cancer, we acquired quantitative peptidome
Figure 1. Schematic view of peptidome biomarker development workflow. In the screening phase, 92 serum samples were initially heat
inactivated. The peptidome fractions enriched with gel filtration chromatography were analyzed with QSTAR-Elite LC/MS/MS. Following LC/MS data
processing and label-free quantification analysis on the Expressionist RefinerMS module, candidate biomarkers were statistically extracted by the
Expressionist Analyst module. In the validation phase, MRM experiments were performed to assess the applicability of 19 biomarker candidates using
additional 96 serum samples.
doi:10.1371/journal.pone.0018567.g001
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patients that consisted of 32 patients with an operable lung cancer
(stage-I: n=10, stage-II: n=10, stage-IIIa: n=12) and 30 lung
cancer patients at an advanced stage (stage-IIIb: n=15, stage-IV:
n=15) to identify candidate serum biomarkers for lung cancer.
The serum samples were purified using gel filtration chromatog-
raphy as described above and individually subjected to LC/MS/
MS analyses using QSTAR-Elite mass spectrometer (Fig. 1).
Subsequently 92 MS raw data were loaded and processed on the
Expressionist RefinerMS module (Fig. 3A). Genedata Expressionist
is an enterprise system for omics data management comprised of
integrated software modules, which support the complete R&D
processes involving data processing, statistical analysis, data
management and result reporting. The technology-dependent
modules for microarray data (Refiner Array), mass spectrometry
(Refiner MS, used in the present study) and genomic profiling
(Refiner Genome) allow highly-sophisticated data processing,
quantification, visualization, and result exporting in any general-
ly-used formats. Once all data are quantified and summarized,
they can be seamlessly analyzed with the Genedata Analyst
module employing various statistical analyses. This system initially
made the MS chromatogram planes as shown in Figure 3C, and
subtracted the instrument specific noises and chemical noises
effectively. At the fourth step of the workflow in Figure 3A, the
retention time (RT) grids on each MS chromatogram plane were
perfectly aligned among these 92 samples (Fig. 3B), which allowed
the solid quantification analysis of multiple samples. Subsequently,
peaks were detected from temporarily averaged m/z-RT planes by
the Chromatogram Summed Peak Detection Activity in order to
avoid missing peak-location information even if the peaks were not
detectable in particular planes. The detected isotopic peaks
belonging to the same peptide signals were grouped into individual
clusters that are displayed as colored rectangles in Figure 3C.A
total of 12,396 non-redundant isotopic peak clusters with charge
state +1t o+10 were detected from 92 serum samples. We then
utilized 3,537 clusters with charge stage +2t o+10 for further
statistical considerations in the Expressionist Analyst module, since
singly-charged ions might include substantial proportion of non-
peptide components such as chemicals.
Student’s t-test was applied to investigate the differences in their
serum levels between the normal group (n=30) and the lung cancer
group (n=62) (Fig. 4A). This analysis identified 118 candidate
biomarker peptides (p,0.01 and fold-change of .5.0). Since the
criteria of t-test were variable for the purpose of candidate selection,
we used the threshold above just in order to define the highest
priority group. The intensity distributions of these peptides were
Figure 2. Simple and efficient enrichment of serum peptidome fractions by gel filtration chromatography. (A) The merged display of
16 independent spectra of gel filtration chromatography (280 nm UV absorbance). 10 ml each of serum sample was loaded. The upper right box
shows the magnified view of the retention time range from 20 to 50 minutes. (B)(C) To evaluate the fractionation efficacy of Superdex Peptide 10/300
column, the elute was separated into 10 fractions and analyzed with MALDI-TOF mass spectrometer. The numbers of fractions in B correspond to the
spectra numbers in C.
doi:10.1371/journal.pone.0018567.g002
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component analysis demonstrated that the values of 118 candidate
biomarker peptides could explicitly separate control and lung
cancer groups on the 3D plot using principal component 1, 2, and 3
(Fig. 4B). The proportion of variance described by the principal
component 1, 2, or 3 was 66.9%, 15.0%, or 4.4%, respectively,
indicating that illustrated components 1 to 3 could reflect 86.3%
(the cumulative proportion) of quantitative information in this mass
spectrometric screening analysis.
Identification of peptide sequences by LC/MS/MS
Alongside the label-free quantification-based biomarker
screening described above, the comprehensive peptide sequenc-
ing was performed by a combination of QSTAR-Elite LC/MS/
MS analysis and MASCOT database search. Among 230,657
MS/MS queries from 92 serum samples, 5,382 peptides were
successfully sequenced with MASCOT expectation value ,0.05
(FDR of peptide matches above Identity threshold was 1.49%).
After examining redundancy, 424 unique peptides were
Figure 3. Rapid and accurate data processing for label-free quantification on the Expressionist RefinerMS module. (A) The total
workflow used in the Expressionist RefinerMS module. Only 3 hours were needed to complete entire steps in this workflow on 92 LC/MS/MS data
(each with 120 minutes LC gradient). (B) The representative area of m/z - retention time planes after RT alignment of 92 LC/MS/MS data. In each
panel, three isotopic clusters and grid lines were displayed, showing highly exact alignments. (C) The MS chromatogram plane in which all data
processing were completed. Finally, isotopic clusters derived from a single peptide were grouped into a colored cluster as shown in the middle panel.
The far right panel shows the MS spectrum corresponding to the horizontal section view of a representative cluster.
doi:10.1371/journal.pone.0018567.g003
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Regarding the 118 candidate peptides, 19 peptides were
uniquely identified; 12 of them were found to be derivatives
from fibrinogen alpha chain (FIBA), 4 from apolipoprotein A-
IV (APOA4), and the remaining three peptides were turned out
to be a fragment of amiloride-sensitive cation channel 4
(ACCN4), apolipoprotein E (APOE), and limbin (LBN)
(Table 1).
MRM-based validation experiment for 19 candidate
biomarker peptides
To assess the quantitative reproducibility of the label-free
quantification results in our single-run screening analysis, as well as
the clinical usefulness of the 19 candidate biomarkers, we
conducted further validation studies by multiple reaction moni-
toring (MRM) technology using 96 additional serum samples
(Table S1). For designing the optimum MRM transitions specific
Figure 4. Statistical identification of candidate biomarkers for lung cancer. (A) The hierarchy chart of clusters (peptides) according to
Student’s t-test p-values (normal group vs. lung cancer group). 118 peptides satisfied the criteria of p,0.01 and fold change .5.0. (B) Principal
component analysis using the values of 118 candidate biomarker peptides showed clear separation between control and lung cancer groups on the
3D plot. The proportion of variance described by the principal component 1, 2, or 3 was 66.9%, 15.0%, or 4.4%, respectively.
doi:10.1371/journal.pone.0018567.g004
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detected in the screening phase were set as Q1 channels and those
of four most intense fragment ions were selected from each MS/
MS spectrum for Q3 channels (Fig. S2 and Table S3). Hence, a
total of 76 MRM transitions were simultaneously monitored by
4000 QTRAP mass spectrometry using a serum peptidome sample
(Fig. 5). We then determined the specific eluting retention time for
each candidate peptide and selected the optimum MRM
transitions showing the highest MRM chromatogram peak out
of four transitions for each peptide (Table S4). In our
observations, only two peptides (FIBA 3–16 and FIBA 5–16)
showed the identical orders of fragment ion intensities between
QSTAR-Elite and 4000 QTRAP systems as shown in Figure 5.
We further performed MRM-based relative quantification
analysis using 36 normal controls and 60 lung cancer samples
in duplicated experiments. The serum levels of 19 candidate
biomarker peptides were calculated on the basis of normalized
and averaged MRM chromatogram peak areas and displayed
with box plots (Fig. 6A). To evaluate the efficacy of these
candidates for early detection of lung cancer, we compared the
earlier-stage lung cancer group (stage-I, II, and IIIa) with the
normal group by Student’s t-test. The results revealed that 15 out
of 19 candidate peptides showed significant differences in their
serum levels between the two groups, while 4 peptides (FIBA 4–
15, FIBA 5–15, FIBA 7–15, and FIBA 7–16) showed no
significant differences. Concerning the comparison between the
normal group and the advanced-stage lung cancer group (stage-
IIIb and IV), similarly 4 peptides (APOA4 268–284, APOA4
271–283, FIBA 5–15, and APOE 194–214) did not satisfy the
criterion of p,0.05. Hence, we considered that the remaining 12
peptides are likely to be more promising biomarkers for lung
cancer diagnosis. We next assessed the sensitivity and specificity
of the 19 biomarkers for lung cancer diagnosis by ROC curve
analysis (Fig. 6B and Fig. S3). The cut-off value was set at the
point whose distance from the (sensitivity, specificity) = (1, 1)
reached the minimum. Given the value of sensitivity to detect
lung cancer at an earlier stage, FIBA 6–15 (87.1%), APOA4 273–
283 (61.3%), FIBA 5–16 (58.1%), and LBN 306–313 (58.1%)
appeared to be the good biomarker candidates. However
although the specificity of APOA4 273–283, FIBA 5–16, and
LBN 306–313 were remarkably higher (88.9%, 94.4%, and
100%, respectively, Fig. 6B), FIBA 6–15 showed relatively lower
specificity (44.4%) and the area under the curve (0.641). By
integrating the results from t-test and ROC curve analysis, the 3
candidates shown in Figure 6B were considered as the most
promising peptide biomarkers for early detection of lung cancer.
Discussion
Even though recent mass spectrometry instruments have
allowed measurements of peptide mixtures at high sensitivity
[24], enrichment of targeted proteins/peptides is still indispensable
to achieving detection and identification of serum components in
limited amounts of biological materials. In this sense, the
methodology to purify preanalytical samples without loss of
targeted components is crucial. From this point of view, the
previous peptidome profiling technologies, such as SELDI-TOF-
MS coupled with ProteinChip arrays or MALDI-TOF-MS
Table 1. 19 lung cancer biomarker candidates.
Expressionist
a MASCOT
b
Cluster ID
c m/z RT z t-test p-value
d Acc.
e start end Peptide sequence
Cluster_3187 551.8 64.1 2 1.54E-15 ACCN4 613 624 CPSLGRAEGGGV
Cluster_3858 750.9 60.3 2 7.85E-04 APOA4 271 283 ELGGHLDQQVEEF
Cluster_3444 629.8 52.2 2 9.41E-07 APOA4 268 284 GGHLDQQVEEF
Cluster_3661 689.8 75.3 2 8.52E-08 APOA4 260 284 GNTEGLQKSLAELGGHLDQQVEEFR
Cluster_3498 643.3 65.7 2 6.08E-05 APOA4 288 304 SLAELGGHLDQQVEEFR
Cluster_2454 756.4 65.6 3 2.93E-03 APOE 194 214 TVGSLAGQPLQERAQAWGERL
Cluster_248 768.8 53.0 2 6.41E-23 FIBA 1 16 ADSGEGDFLAEGGGVR
Cluster_126 432.7 62.6 2 3.07E-22 FIBA 7 15 DFLAEGGGV
Cluster_159 510.7 49.9 2 5.75E-25 FIBA 7 16 DFLAEGGGVR
Cluster_240 733.3 56.5 2 3.80E-15 FIBA 2 16 DSGEGDFLAEGGGVR
Cluster_166 525.7 62.8 2 2.99E-25 FIBA 5 15 EGDFLAEGGGV
Cluster_3342 603.8 50.7 2 8.17E-27 FIBA 5 16 EGDFLAEGGGVR
Cluster_2872 461.2 61.8 2 3.31E-12 FIBA 6 15 GDFLAEGGGV
Cluster_174 539.3 52.3 2 4.10E-15 FIBA 6 16 GDFLAEGGGVR
Cluster_180 554.2 63.5 2 5.37E-22 FIBA 4 15 GEGDFLAEGGGV
Cluster_207 632.3 52.1 2 1.98E-21 FIBA 4 16 GEGDFLAEGGGVR
Cluster_196 597.8 63.2 2 4.44E-24 FIBA 3 15 SGEGDFLAEGGGV
Cluster_221 675.8 52.3 2 2.22E-22 FIBA 3 16 SGEGDFLAEGGGVR
Cluster_135 453.2 39.0 2 2.81E-24 LBN 306 313 FLLSLVLT
aInformation acquired from the Expressionist RefinerMS or the Analyst module.
bInformation acquired from MASCOT database search.
cEach ID corresponds to that in the bar chart (Fig. S1).
dShown is the p-value of t-test between normal group and lung cancer group.
eUniProt Accession Number.
doi:10.1371/journal.pone.0018567.t001
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limited spectra of serum peptidome. Most of studies utilizing ion-
exchange selection or reversed phase extraction of peptidome on
ProteinChip arrays [25,26,27] or magnetic beads [28,29] allowed
at most 200 peak detections within the mass range 1,000 to
20,000. Meanwhile our peptidome profiling technology consisting
of gel-filtration chromatography, custom-made high resolution
C18 tip-column, QSTAR-Elite mass spectrometer, and Expres-
sionist proteome server platform analysis enabled us to detect
12,396 non-redundant molecules with charge state of +1t o+10.
The number of detected peaks here denoted the enormous
advantage of our methodology for the analytical comprehensive-
ness compared to other existing methods. Although we focused on
serum peptides involved in 3,537 clusters with charge stage of +2
to +6 in this study, 12,396 clusters might include non-peptide
serum components such as metabolites, which should be also
valuable for biomarker screening. Additionally, regarding the
capacity of sample numbers to be analyzed simultaneously, the
Expressionist server platform has a potential to handle a larger
number of clinical samples. Because we in fact needed only less
than an hour to process 92 LC/MS/MS data in the Refiner MS
module (Fig. 1A), a comprehensive analysis of up to 1,000 cases
would be feasible in a day. Hence our peptidome profiling
technology provides the outstanding features of data comprehen-
siveness and quantitative performance, which absolutely fit the in-
depth screening of novel biomarkers from clinical samples such as
serum and plasma compared to previous technologies described
above, whereas estimating actual dynamic range of detected
peptide concentrations would be needed by,for instance, MRM-
based absolute quantification analysis in the future. It could be
tailored to many diagnostic and pharmaco-dynamic purposes as
comprehensive interpretations of catalytic and metabolic activities
in body fluids or tissues.
By using this technology, we finally identified 19 serum peptides
as candidate lung cancer biomarkers (Table 1). The subsequent
MRM-based validation experiments and t-test resulted in the
confirmation of 12 candidates as reliable lung cancer biomarkers
(Fig. 6A). Eight of them were fragments derived from fibrinopep-
Figure 5. Selection and confirmation of the optimum MRM transitions for 19 candidates. Four pairs of precursor m/z and fragment m/z
(Q1/Q3 channels) were set as MRM transitions for each peptide. The blue, red, green, or gray MRM chromatogram monitored the fragment ion which
showed the 1
st,2
nd,3
rd,o r4
th most intense peaks in QSTAR-Elite LC/MS/MS analysis, respectively.
doi:10.1371/journal.pone.0018567.g005
Peptidome Profiling for Lung Tumormarker Discovery
PLoS ONE | www.plosone.org 9 April 2011 | Volume 6 | Issue 4 | e18567Peptidome Profiling for Lung Tumormarker Discovery
PLoS ONE | www.plosone.org 10 April 2011 | Volume 6 | Issue 4 | e18567tide A (FPA) which is N terminally cleaved product from
fibrinogen a (FIBA). In fact, both our screening and validation
results suggested that all of these eight FPA fragments were
potential lung cancer-associated biomarkers showing the signifi-
cant increase of concentrations in lung cancer patients’ sera.
However, since anomalous turnover of FPA was previously
reported in several other diseases including gastric cancer [30],
diabetic nephropathy [31], coronary heart disease [32], and
others, these 8 FPA fragments could not be defined as lung cancer-
specific biomarkers. The other two candidates were generated
from apolipoprotein A-IV (APOA4). APOA4 protein itself was
already identified as an up-regulated biomarker for ovarian cancer
[33], whereas this was also known to be regulated by nutritional
and metabolic stress [34]. But both quantitative information and
physiological functions of endogenously-processed APOA4 pep-
tides in human serum were still unknown. Interestingly, the
APOA4 273–283 fragment demonstrated pathological stage-
dependent up-regulation in lung cancer patients’ sera, while the
two-residue longer fragment APOA4 271–283 was significantly
decreased in lung cancer samples (Fig. 6A). This indicates the
existence of lung cancer-associated endo- or exopeptidases
responsible for the cleavage at the C-terminus of APOA4 a.a.
272. Additional two candidate biomarkers, LBN 306–313 and
ACCN4 613–624, derived from limbin (LBN) and amiloride-
sensitive cation channel 4 (ACCN4) proteins, were reported as
cellular membrane proteins. LBN is also known as Ellis-van
Creveld syndrome 2 (EVC2) that is expressed in the heart,
placenta, lung, liver, skeletal muscle, kidney and pancreas. Defects
in LBN (EVC2) are a cause of acrofacial dysostosis Weyers type
(WAD, also known as Curry-Hall syndrome) [35]. ACCN4 is a
newly identified member of the acid-sensing ion channel family
expressed in pituitary gland and weakly in brain [36]. Neither of
them was detected in serum previously. Since our study provided
the first evidence of LBN 306–313 and ACCN4 613–624 detection
in human serum, further analysis of physiological functions and
measurement inotherdiseasesshould be required forthe proper use
in clinical lung cancer diagnosis. Hence, the three candidate
biomarkers illustrated in Figure 6B (APOA4 273–283, FIBA 5–16,
and LBN 306–313) were individually considered as clinically useful
biomarkers for both early detection and tumor staging of lung
cancer, however, integrative measurement of biomarkers such as
Figure 4B would provide more accurate diagnosis, that could be
achievable by MRM-based diagnostic approaches in the future.
Consequentlythesensitivityofthesebiomarkerswashigherthanthe
currently-used screening biomarker CEA especially at even stage-I
or II [8], indicating that new biomarkers addressed in this study had
great potential to realize the early detection system for lung cancer.
However further validation experiments using high risk groups of
lung cancer as the controls (such as heavy smokers or COPD
patients) will be necessary to prove the specificity and clinical
usefulness of our biomarkers because more practical target
population of the early diagnosis of lung cancer should be them
rather than healthy individuals.
Finally we grasped the birds-eye view of human peptidome as a
snapshot of the specific disease state. We are recently willing to use
our peptidome profiling technology to establish an in-house
quantitative serum/plasma peptidome database and contribute to
the worldwide efforts such as Peptide Atlas (http://www.
peptideatlas.org/). This framework would represent a new insight
of protease/peptidase activities reflecting a clinical status at a
specific time-point of disease and provide essential resources for
next-generation extracorporeal diagnostic systems based on mass
spectrometry. We therefore hope that researchers at global sites
would utilize the peptidome profiling method addressed here and
share data to construct mutually beneficial networks and databases
which could contribute to the development of future diagnostic
technologies worldwide.
Supporting Information
Figure S1 The bar charts illustrating the quantitative screening
results for 19 candidates. The normalized peak intensities of 118
candidate biomarker peptides were calculated from 92 serum
samples and displayed with bar charts.
(TIF)
Figure S2 MS/MS spectra used for the construction of MRM
transitions and peptide identification. All MS/MS spectra were
acquired with QSTAR-Elite mass spectrometer in the screening
phase (the upper panels). The 1
st,2
nd,3
rd,o r4
th most intense
peaks in each MS/MS spectrum were used for the optimization of
MRM transitions (Fig. 5) The middle and the lower panels show
the identified fragment ions in MASCOT database search. The
ion scores and Expectation values were also indicated in the lower
panels.
(TIF)
Figure S3 ROC curves for 19 lung cancer biomarker candidates
were depicted by R. The green or blue graph shows comparison of
‘‘normal group (n=36) and lung cancer stage-I, II, and IIIa
(n=30)’’ or ‘‘normal group (n=36) and lung cancer stage-IIIb and
IV (n=30)’’, respectively. The cut-off value was set at the point
whose distance from the (sensitivity, specificity) = (1, 1) reached
the minimum. The sensitivity (Sens), specificity (Spec), positive
predictive value (PV+), negative predictive value (PV-), and area
under the curve (AUC) were shown on each graph.
(TIF)
Table S1
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